Micofenolato De Mofetilo Tecnigen

Mycophenolate Mofetil, the active ingredient in Micofenolato De Mofetilo Tecnigen, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to prevent acute rejection in organ transplantation and to treat certain autoimmune kidney disorders.

GNH USA supplies Micofenolato De Mofetilo Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil acts on the immune system to reduce lymphocyte proliferation, making it useful in several transplant‑related and autoimmune conditions. - Kidney transplantation: helps prevent acute graft rejection and supports long‑term graft survival. - Heart transplantation: reduces the risk of early and late rejection episodes. - Liver transplantation: maintains graft function by suppressing immune activation. - Lupus nephritis: diminishes renal inflammation and proteinuria in systemic lupus erythematosus. - Autoimmune disorders: provides immunosuppression for selected severe autoimmune diseases.

Adverse reactions may range from mild to severe and should be monitored throughout therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, sometimes leading to dehydration. - Abdominal pain: cramping or discomfort in the stomach area. - Headache: transient mild to moderate pain. - Infections: increased susceptibility to bacterial, viral, or fungal infections. - Leukopenia: reduced white blood cell count, raising infection risk.

Serious or Rare Side Effects: - Severe neutropenia: markedly low neutrophil levels, potentially life‑threatening. - Opportunistic infections: such as Pneumocystis jirovecii pneumonia. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Malignancy: increased long‑term risk of certain cancers. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease. - Gastrointestinal perforation: rare but serious abdominal emergency.

Patients receiving Mycophenolate Mofetil require careful monitoring and specific safety measures. - Blood counts: monitor complete blood count regularly to detect leukopenia or neutropenia. - Renal function: assess serum creatinine and glomerular filtration rate periodically. - Pregnancy: avoid use during pregnancy (Category D) and ensure effective contraception. - Breastfeeding: contraindicated; do not breastfeed while on therapy. - Hepatic impairment: dose adjustment may be needed in patients with liver dysfunction. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Mycophenolate Mofetil can interact with several drugs, altering efficacy or safety.

Major Interactions (Avoid): - Rifampin or other strong CYP3A4 inducers: may markedly reduce drug exposure. - Live vaccines: increased risk of vaccine‑derived infection. - Cholestyramine or other bile‑acid sequestrants: can decrease absorption.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression; monitor blood counts. - Calcineurin inhibitors (tacrolimus, cyclosporine): may increase mycophenolate levels; adjust dose as needed. - ACE inhibitors or ARBs: combined use may worsen renal function; monitor creatinine. - NSAIDs: concurrent use can impair renal perfusion; watch for kidney injury.